A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.

"The authors of this manuscript have conflicts of interest to disclose. Chadban S: Received research funding, honoraria or travel support from Novartis, Wyeth, Jansen, BMS and Genzyme. Kanellis J: Received research funding, honoraria or travel support from Novartis, Roche, Wyeth, BMS and Genzyme. Pilmore H: Received honoraria from Roche. Lee PC: No relevant conflicts to disclose. Lim SK: Received research funding, honorarium from Roche, Sanofi, Boehringer Ingelheim. Woodcock C: Employed by Novartis Pharmaceuticals Australia. Kurstjens N: Employed by Novartis Pharmaceuticals Australia. Eris J: Received research funding &/or honoraria &/or travel support from Novartis, Roche, Pfizer, Amgen, Astellas and Jansen Cilag. Russ G: Received research funding, honoraria or travel support from Novartis, Wyeth, Bristol-Myers Squibb and Astellas."

"Funding The study was sponsored by Novartis Pharmaceuticals."

"SOCRATES was registered on ClinicalTrials.gov and identified by the code NCT00371826."